Genetic Technologies Ltd. ADR (GENE): Price and Financial Metrics


Genetic Technologies Ltd. ADR (GENE): $1.06

-0.01 (-0.93%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GENE Stock Summary

  • With a market capitalization of $19,760,685, GENETIC TECHNOLOGIES LTD has a greater market value than just 8.47% of US stocks.
  • With a year-over-year growth in debt of -59.48%, GENETIC TECHNOLOGIES LTD's debt growth rate surpasses just 4.07% of about US stocks.
  • Revenue growth over the past 12 months for GENETIC TECHNOLOGIES LTD comes in at 86,990.22%, a number that bests 99.98% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to GENETIC TECHNOLOGIES LTD are MRSN, NCTY, MDGS, ARQQ, and VACC.
  • Visit GENE's SEC page to see the company's official filings. To visit the company's web site, go to www.gtglabs.com.

GENE Stock Price Chart Interactive Chart >

Price chart for GENE

GENE Price/Volume Stats

Current price $1.06 52-week high $2.40
Prev. close $1.07 52-week low $0.83
Day low $1.06 Volume 111,868
Day high $1.10 Avg. volume 2,613,392
50-day MA $1.19 Dividend yield N/A
200-day MA $1.26 Market Cap 20.39M

Genetic Technologies Ltd. ADR (GENE) Company Bio


Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. It operates through the USA and Australia geographical segments. The firm's product BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.


GENE Latest News Stream


Event/Time News Detail
Loading, please wait...

GENE Latest Social Stream


Loading social stream, please wait...

View Full GENE Social Stream

Latest GENE News From Around the Web

Below are the latest news stories about GENETIC TECHNOLOGIES LTD that investors may wish to consider to help them evaluate GENE as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off another day of trading with a look at the biggest pre-market stock movers investors need to watch for Wednesday!

William White on InvestorPlace | February 9, 2023

New Publication Highlights geneType’s Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

MELBOURNE, Australia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the publication of a new research paper in the peer-reviewed journal Breast Cancer Research and Treatment. Highlights: GeneType outperforms 5-year and remaining lifetime risk prediction compared to the commonly used clinical models Gail and IBISv7, respectively.The

Yahoo | February 9, 2023

Genetic Technologies Announces Closing of $5 Million Registered Direct Offering

MELBOURNE, Australia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced the closing of its previously announced registered direct offering with several institutional investors for the purchase and sale of 3,846,155 American Depositary Shares (“ADSs”), each representing six hundred (600) ordinary shares

Yahoo | February 7, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with an overview of the biggest pre-market stock movers traders need to know about for Monday!

William White on InvestorPlace | February 6, 2023

Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer

MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is delighted to provide further update. The innovation and development of this test is inspired by direct response and feedback from the payer conversations such as insurance providers, employers, and healthcare providers. There is an unmet need to develop a unique single saliva risk asses

Yahoo | February 6, 2023

Read More 'GENE' Stories Here

GENE Price Returns

1-mo -21.48%
3-mo 3.92%
6-mo -24.29%
1-year -48.24%
3-year -37.28%
5-year -79.30%
YTD 13.98%
2022 -50.53%
2021 -47.78%
2020 80.90%
2019 -9.54%
2018 -52.59%

Continue Researching GENE

Want to see what other sources are saying about Genetic Technologies Ltd's financials and stock price? Try the links below:

Genetic Technologies Ltd (GENE) Stock Price | Nasdaq
Genetic Technologies Ltd (GENE) Stock Quote, History and News - Yahoo Finance
Genetic Technologies Ltd (GENE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8138 seconds.